# US 11,077,163 B2 · Peptide for treating ocular diseases and composition for treating ocular diseases comprising same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,077,163 B2
- Document ID: US11077163B2
- Status: Granted
- Kind: B2
- Application number: 16/582,014
- Filed: 2019-09-25
- Published: 2020-01-16
- Granted: 2021-08-03
- Earliest claimed: 2019-09-25
- Assignees: GemVax & KAEL Co., Ltd.
- Applicants: GemVax & KAEL CO., LTD.
- Inventors: Sang Jae Kim
- Web page: https://patentgrep.com/patent/US11077163B2

## CPC

- A61K 38/005: {Enzyme inhibitors (protease inhibitors A61K38/55)}
- A61K 38/02: Peptides of undefined number of amino acids; Derivatives thereof
- A61K 38/06: Tripeptides
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- C07K 1/045: {using devices to improve synthesis, e.g. reactors, special vessels}
- C07K 1/061: {using protecting groups}
- C07K 1/10: using coupling agents {(C07K1/006 takes precedence)}
- C07K 1/16: by chromatography
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A pharmaceutical composition for preventing or treating ophthalmopathy is described. More particularly, a composition comprising a peptide derived from telomerase and being effective in treating and preventing ophthalmopathy is described. The peptide derived from telomerase, a peptide having a sequence 80% identical to the sequence thereof, or a peptide as a fragment thereof is superiorly effective in treating ophthalmopathy.

## Claims

### Claim 1

A method of inhibiting choroidal neovascularization, comprising:
administering to a subject in need thereof an effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 1.

### Claim 2 (depends on 1)

The method of claim 1, wherein the peptide is administered at a daily dose of 10 ng/kg to 10 mg/kg.

### Claim 3 (depends on 1)

The method of claim 1, wherein the peptide is administered at a daily dose of 2 μg/kg to 50 μg/kg.

### Claim 4 (depends on 1)

The method of claim 1, wherein the peptide is administered 1 to 3 times a day.

### Claim 5

A method of inhibiting choroidal neovascularization, comprising:
administering to a subject in need thereof a composition comprising an effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 1.

### Claim 6 (depends on 5)

The method of claim 5, wherein the composition further comprises a pharmaceutically acceptable excipient and an additive.

### Claim 7 (depends on 5)

The method of claim 5, wherein the composition is a food composition.

### Claim 8 (depends on 5)

The method of claim 5, wherein the composition comprises 0.01 g/L to 1 kg/L of the peptide.

### Claim 9 (depends on 5)

The method of claim 5, wherein the composition comprises 1 g/L to 10 g/L of the peptide.

### Claim 10 (depends on 5)

The method of claim 5, wherein the peptide is administered at a daily dose of 10 ng/kg to 10 mg/kg.

### Claim 11 (depends on 5)

The method of claim 5, wherein the peptide is administered at a daily dose of 2 μg/kg to 50 μg/kg.

### Claim 12 (depends on 5)

The method of claim 5, wherein the peptide is administered 1 to 3 times a day.